Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Docetaxel in Breast Cancer Patients
This study has been completed.
Study NCT00174707   Information provided by Sanofi-Aventis
First Received: September 12, 2005   Last Updated: July 30, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Neoplasms
Additional conditions recognized in this trial
Neoplasms
More general conditions related to this trial
Breast Diseases
Neoplasms by Site
Skin Diseases
Additional drug interventions recognized in this trial
Cyclophosphamide
Docetaxel
Epirubicin
Methotrexate
More general drug interventions related to this trial
Abortifacient Agents
Abortifacient Agents, Nonsteroidal
Alkylating Agents
Antibiotics, Antineoplastic
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses
Sponsors listed in this trial
Sanofi-Aventis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services